top
Please input keywords
OK
Database
Family Website
Eucure Biopharma
Biocytogen Boston Corp.
홍보센터
Contact us
KR
CN
EN
JP
회사소개
회사소개
회사 연혁
핵심인력
기업문화
사회적 책임
인재모집
합작연구개발
파이프라인
RenMice™ HiTS Platform
기술 플랫폼
핵심연구분야
신약개발 프로세스
RenMice
동물/세포 모델
동물/세포모델
질병 모델
유전자 편집
Investor Relations
Home
News events
자료 다운로드
포스터 다운로드
홍보센터
뉴스 및 각종 자료 열람
뉴스
공지사항
웨비나
논문게재실적
자료 다운로드
포스터 다운로드
제품정보 다운로드
2023
AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
2023
AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
2023
AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
2023
AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1
2023
AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
2023
AACR 2023: RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
1
2
3
4
5
…
7
GO
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html